Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Presentation / Abstract • Phase 3ATS oral symposium Wed, May 20, 2026, 8:30 AM ET
Company profile
Achieve Life Sciences
Pipeline1 asset
- cytisiniclinenicotinic acetylcholine receptor / plant-derived alkaloid; partial agonist / nicotine dependencesmoking cessation in adultsNDA accepted; PDUFA June 20, 2026under FDA reviewUSe-cigarette or vaping cessationPhase 2 completed; Phase 3 design agreedBreakthrough Therapy designation; FDA CNPVUS
Latest news14 items
All newsAchieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Presentation / Abstract • Phase 3